fluoxetine has been researched along with Breast Neoplasms in 20 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| " With this in mind, a single-arm clinical trial low-dose regimen of Fluoxetine (10 mg/day for 4 weeks) was given to twenty symptomatic breast cancer patients." | 9.11 | Hot-flashes in breast cancer survivors: effectiveness of low-dosage fluoxetine. A pilot study. ( Atlante, M; Barbati, A; Galati, M; Giannarelli, D; Mariani, L; Quattrini, M, 2005) |
| "This trial used a double-blinded, randomized, two-period (4 weeks per period), cross-over methodology to study the efficacy of fluoxetine (20 mg/d) for treating hot flashes in women with a history of breast cancer or a concern regarding the use of estrogen (because of breast cancer risk)." | 9.10 | Phase III evaluation of fluoxetine for treatment of hot flashes. ( Halyard, MY; Loprinzi, CL; Mailliard, JA; Novotny, PJ; Perez, EA; Pruthi, S; Quella, SK; Rummans, TA; Sloan, JA; Stella, PJ, 2002) |
| "We studied the effect of fluoxetine, an SSRI, on the development of brain metastatic breast cancer using MDA-MB-231BR cells in a mouse model." | 7.80 | Fluoxetine modulates breast cancer metastasis to the brain in a murine model. ( Amico-Ruvio, SA; Brown, EB; Dickerson, IM; Kelly, EA; Majewska, AK; Shapovalov, Y; Sipe, GO; Spielman, SC; Zettel, M, 2014) |
| "Triple negative breast cancer (TNBC) is a complex and intrinsically aggressive tumour with poor prognosis, and the discovery of targeted small-molecule drugs for TNBC treatment still remains in its infancy." | 5.48 | Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer. ( Chen, L; Jiang, Y; Ouyang, L; Sun, D; Yu, Y; Zhao, Y; Zhu, L, 2018) |
| "Breast cancer is one of the most common types of malignancies in females worldwide." | 5.43 | Ameliorative potential of fluoxetine/raloxifene combination on experimentally induced breast cancer. ( Elkhoely, AA; Kabel, AM, 2016) |
| " With this in mind, a single-arm clinical trial low-dose regimen of Fluoxetine (10 mg/day for 4 weeks) was given to twenty symptomatic breast cancer patients." | 5.11 | Hot-flashes in breast cancer survivors: effectiveness of low-dosage fluoxetine. A pilot study. ( Atlante, M; Barbati, A; Galati, M; Giannarelli, D; Mariani, L; Quattrini, M, 2005) |
| "This trial used a double-blinded, randomized, two-period (4 weeks per period), cross-over methodology to study the efficacy of fluoxetine (20 mg/d) for treating hot flashes in women with a history of breast cancer or a concern regarding the use of estrogen (because of breast cancer risk)." | 5.10 | Phase III evaluation of fluoxetine for treatment of hot flashes. ( Halyard, MY; Loprinzi, CL; Mailliard, JA; Novotny, PJ; Perez, EA; Pruthi, S; Quella, SK; Rummans, TA; Sloan, JA; Stella, PJ, 2002) |
| " We demonstrated the combinations of doxorubicin (DOX) + artesunate, DOX + chloroquine, paclitaxel (PTX) + fluoxetine, PTX + fluphenazine, and PTX + benztropine induce significant cytotoxicity in Michigan Cancer Foundation-7 (MCF-7) breast cancer cells." | 4.12 | Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action. ( Duarte, D; Nunes, M; Ricardo, S; Vale, N, 2022) |
| "We studied the effect of fluoxetine, an SSRI, on the development of brain metastatic breast cancer using MDA-MB-231BR cells in a mouse model." | 3.80 | Fluoxetine modulates breast cancer metastasis to the brain in a murine model. ( Amico-Ruvio, SA; Brown, EB; Dickerson, IM; Kelly, EA; Majewska, AK; Shapovalov, Y; Sipe, GO; Spielman, SC; Zettel, M, 2014) |
| ", paroxetine, fluoxetine) in patients treated with tamoxifen for breast cancer." | 3.79 | Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. ( Bannink, M; Binkhorst, L; Jager, A; Mathijssen, RH; van Gelder, T; van Herk-Sukel, MP; Wiemer, EA, 2013) |
| "Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or estrogen deficiency state." | 2.73 | Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. ( Brenner, MC; Navari, RM; Wilson, MN, 2008) |
| "Triple negative breast cancer (TNBC) is a complex and intrinsically aggressive tumour with poor prognosis, and the discovery of targeted small-molecule drugs for TNBC treatment still remains in its infancy." | 1.48 | Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer. ( Chen, L; Jiang, Y; Ouyang, L; Sun, D; Yu, Y; Zhao, Y; Zhu, L, 2018) |
| "Breast cancer is one of the most common types of malignancies in females worldwide." | 1.43 | Ameliorative potential of fluoxetine/raloxifene combination on experimentally induced breast cancer. ( Elkhoely, AA; Kabel, AM, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Germain, AR | 1 |
| Carmody, LC | 1 |
| Nag, PP | 1 |
| Morgan, B | 1 |
| Verplank, L | 1 |
| Fernandez, C | 1 |
| Donckele, E | 1 |
| Feng, Y | 1 |
| Perez, JR | 1 |
| Dandapani, S | 1 |
| Palmer, M | 1 |
| Lander, ES | 1 |
| Gupta, PB | 1 |
| Schreiber, SL | 1 |
| Munoz, B | 1 |
| Duarte, D | 1 |
| Nunes, M | 1 |
| Ricardo, S | 1 |
| Vale, N | 1 |
| Lei, B | 1 |
| Xu, L | 1 |
| Zhang, X | 1 |
| Peng, W | 1 |
| Tang, Q | 1 |
| Feng, C | 1 |
| Sun, D | 1 |
| Zhu, L | 1 |
| Zhao, Y | 1 |
| Jiang, Y | 1 |
| Chen, L | 1 |
| Yu, Y | 1 |
| Ouyang, L | 1 |
| Binkhorst, L | 1 |
| Mathijssen, RH | 1 |
| van Herk-Sukel, MP | 1 |
| Bannink, M | 1 |
| Jager, A | 1 |
| Wiemer, EA | 1 |
| van Gelder, T | 1 |
| Shapovalov, Y | 1 |
| Zettel, M | 1 |
| Spielman, SC | 1 |
| Amico-Ruvio, SA | 1 |
| Kelly, EA | 1 |
| Sipe, GO | 1 |
| Dickerson, IM | 1 |
| Majewska, AK | 1 |
| Brown, EB | 1 |
| Kabel, AM | 1 |
| Elkhoely, AA | 1 |
| Jenkinson, ML | 1 |
| Shchepotin, IB | 1 |
| Zotov, AS | 1 |
| Dobzhenko, MN | 1 |
| Ong, JC | 1 |
| Sun, F | 1 |
| Chan, E | 1 |
| Zhou, T | 1 |
| Duan, J | 1 |
| Wang, Y | 1 |
| Chen, X | 1 |
| Zhou, G | 1 |
| Wang, R | 1 |
| Fu, L | 1 |
| Xu, F | 1 |
| Kapoor, S | 1 |
| Goetz, MP | 1 |
| Loprinzi, CL | 2 |
| Peer, D | 1 |
| Dekel, Y | 1 |
| Melikhov, D | 1 |
| Margalit, R | 1 |
| Mariani, L | 1 |
| Quattrini, M | 1 |
| Atlante, M | 1 |
| Galati, M | 1 |
| Barbati, A | 1 |
| Giannarelli, D | 1 |
| Navari, RM | 1 |
| Brenner, MC | 1 |
| Wilson, MN | 1 |
| Krishnan, A | 1 |
| Hariharan, R | 1 |
| Nair, SA | 1 |
| Pillai, MR | 1 |
| Cailleux, N | 1 |
| Marie, I | 1 |
| Chrétien, MH | 1 |
| Noblet, C | 1 |
| Lévesque, H | 1 |
| Courtois, H | 1 |
| Sloan, JA | 1 |
| Perez, EA | 1 |
| Quella, SK | 1 |
| Stella, PJ | 1 |
| Mailliard, JA | 1 |
| Halyard, MY | 1 |
| Pruthi, S | 1 |
| Novotny, PJ | 1 |
| Rummans, TA | 1 |
| Marx, J | 1 |
2 reviews available for fluoxetine and Breast Neoplasms
| Article | Year |
|---|---|
[Selective serotonin reuptake inhibitors and mammary pathologies].
Topics: Antidepressive Agents; Breast Neoplasms; Citalopram; Clinical Trials as Topic; Female; Fluoxetine; F | 2010 |
A hot flash on tamoxifen metabolism.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cyclohe | 2003 |
3 trials available for fluoxetine and Breast Neoplasms
| Article | Year |
|---|---|
Hot-flashes in breast cancer survivors: effectiveness of low-dosage fluoxetine. A pilot study.
Topics: Adult; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Fluoxetine; Hot Flashes; Humans; | 2005 |
Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Bre | 2008 |
Phase III evaluation of fluoxetine for treatment of hot flashes.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bayes Theorem; Breast Neoplasms; Chi-Square D | 2002 |
15 other studies available for fluoxetine and Breast Neoplasms
| Article | Year |
|---|---|
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Topics: Amides; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Neopla | 2013 |
Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action.
Topics: Adenosine Diphosphate; Antimalarials; Antineoplastic Agents; Artesunate; ATP Binding Cassette Transp | 2022 |
The proliferation effects of fluoxetine and amitriptyline on human breast cancer cells and the underlying molecular mechanisms.
Topics: Amitriptyline; Antidepressive Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell S | 2021 |
Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Breast Neoplasms; Elongation Factor 2 Kinase; F | 2018 |
Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
Topics: Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6 In | 2013 |
Fluoxetine modulates breast cancer metastasis to the brain in a murine model.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferatio | 2014 |
Ameliorative potential of fluoxetine/raloxifene combination on experimentally induced breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 2016 |
SSRIs and tamoxifen. Why condemn fluoxetine?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Di | 2010 |
Development of stealth liposome coencapsulating doxorubicin and fluoxetine.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Re | 2011 |
Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Dru | 2012 |
Emerging anticarcinogenic effects of fluoxetine besides its role in the treatment of breast carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Female; | 2012 |
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Disease P | 2004 |
Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carrier Proteins; CDC2-CDC28 Kinases; Cell Line, | 2008 |
[Spontaneous hematoma: thoughts about selective serotonin uptake inhibitors].
Topics: Adenocarcinoma; Breast Neoplasms; Dysthymic Disorder; Ecchymosis; Female; Fluoxetine; Hematoma; Huma | 2000 |
Do antidepressants promote tumors?
Topics: Amitriptyline; Animals; Breast Neoplasms; Carcinogens; Female; Fluoxetine; Humans; Mice; Neoplasms, | 1992 |